Q2 2023 Clearwater Paper Corp Earnings Call
Participants
Arsen S. Kitch; CEO, President & Director; Clearwater Paper Corporation
Rebecca Anne Barckley; VP, Corporate Controller, CAO & Interim CFO; Clearwater Paper Corporation
Paul C. Quinn; Director of Paper and Forest Products & Paper and Forest Products Analyst; RBC Capital Markets, Research Division
Sloan Bohlen; MD; SOLEBURY TROUT LLC
Presentation
Operator
Thank you for standing by. My name is Dina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Clearwater Paper's Second Quarter Earnings Conference Call.
(Operator Instructions)
I would like to turn the call over now to Sloan Bohlen, Investor Relations. Sloan, please go ahead.
Sloan Bohlen
Thank you, Dina. Good afternoon, and thank you for Clearwater Paper's Second Quarter 2023 Earnings Conference Call. Joining me on the call today are Arsen Kitch, President and Chief Executive Officer; and Becky Barckley, Corporate Controller and Interim Chief Financial Officer. Financial results for the second quarter of 2023 were released shortly after today's market close, along with the filing of our 10-Q. You will find a presentation of supplemental information, including a slide providing the company's current outlook posted in the Investor Relations page on our website at clearwaterpaper.com.
Additionally, we will be providing certain non-GAAP information in this afternoon's discussion. A reconciliation of the non-GAAP information to comparable GAAP information is included in the press release and in the supplemental information provided on our website. Please note Slide 2 of the supplemental information covering the forward-looking statements rather than reread this slide, we are going to incorporate it by reference into our prepared remarks.
And with that, let me turn the call over to Arsen.
Arsen S. Kitch
Good afternoon, and thank you for joining us today. As you saw in our press release, we had a great second quarter, which was better than we expected, driven by strong operational execution, lower input costs and improved tissue margins. Slide 3 of our supplementals provides a summary of our consolidated results. We reported net sales of $525 million and adjusted EBITDA of $71 million, which is $8 million higher than the second quarter of last year. Our tissue business drove the improvement by more than doubling its adjusted EBITDA from $19 million in the second quarter of last year to $40 million this year.
Let me share a few more highlights with you. Prices increased in both paperboard and tissue as compared to the second quarter of 2022. Lower input costs benefited both of our business as compared to the first quarter of 2023, particularly in fiber, energy and transportation. Operational performance was strong, and we balanced supply and demand to manage our inventories. Tissue private branded share reached an all-time high as consumers continue to look for ways to offset inflation. Our tissue demand remained strong, and we delivered outstanding customer service, while improving our supply chain costs.
Paperboard demand remained soft as customers reduced their inventories due to slowed consumer spending. And finally, we reduced our net debt by $25 million and repurchased 8 million of shares during the quarter, with $15 million remaining on our buyback authorization. With that overview, let me turn to each of our segments and provide some additional details.
Let's begin with our paperboard business on Slide 4. As we noted last year, demand began slowing late in the fourth quarter of last year with that trend continuing through the second quarter of this year. We believe that this was caused by a slowdown in consumer spending and high inventory levels across the value chain. Industry data reflected these trends with a 7.1% decrease in operating rates and a 12.6% decrease in shipments year-to-date 2023 versus year-to-date 2022 based on AF&PA data. As further evidence of this trend, RISI reported a $20 per ton decrease in folding carton prices in July, the first decrease in more than 3 years. Approximately 35% to 40% of our volume is now indexed to RISI, and it typically takes us up to 2 quarters for price changes under these contracts to be reflected in our financials.
While demand remains soft at the beginning of the third quarter, we're expecting an improvement in our volumes in the second half. As I mentioned during our first quarter earnings call, we reduced production in the second quarter to manage our inventories, which resulted in approximately 10% of plant capacity downtime in the second quarter. Our intent is to continue to balance supply and demand for the remainder of the year to get to our targeted inventory levels. While the industry is experiencing a slowdown in demand, we continue to believe that paperboard is economically resilient given the end use of the products. Our portfolio, in particular, skews more heavily towards consumer necessities such as food packaging, pharmaceuticals and cosmetics. We also expect the shift to paper-based products to accelerate with consumers seeking more sustainable packaging and food service products. We believe that this should provide us with more opportunities for growth in the long run.
Please turn to Slide 5 for additional comments on tissue. The performance of our business was very strong with significant improvements in margin driven by higher pricing, higher volume and lower input costs. Adjusted EBITDA more than doubled year-over-year and sequentially to $40 million. Input costs eased between the first and second quarter of this year, particularly in pulp, energy and transportation. Revenue improved by 9% year-over-year, driven by higher pricing and higher retail shipments. Operating performance was also solid, leading to great customer service results with an on-time performance rate of over 95% and a fill rate of over 99%.
The team delivered these results while maintaining inventories at targeted levels and lowering our overall supply chain costs. Let's turn to some broader market data. Private branded tissue share reached an all-time high of 36.3% in June based on Circana panel data. We believe that consumers are continuing to look for better values in their daily purchases to offset inflation and economic uncertainty. Based on RISI data for May, tissue capacity utilization rose to 94.2%, which we believe to be a healthy level. We expect continued strength in our tissue business in the coming quarters as we benefit from strong consumer demand, lower input costs and continued benefits from previously announced price increases. Pulp costs have been on a downward trajectory since the first quarter of this year, with RESI forecasting a continued decline through the rest of the year and relative stability in 2024.
As a reminder, it takes approximately 3 months for changes in pulp prices to be fully reflected in our financials. Transportation availability and costs have also improved greatly since last year, with lower line haul rates positively impacting our financials. With that overview, let me introduce our Corporate Controller and Interim CFO, Becky Barckley. Becky is a key leader in our finance team and has long tenured experience in the forest products industry. Thank you, Becky, for supporting us during this transition.
With that introduction, I will now ask Becky to discuss our second quarter results in more detail.
Rebecca Anne Barckley
Thank you, Arsen. Please turn to Slide 6. The consolidated summary income statement shows results for the second quarter of 2023 and 2022. In the second quarter of '23, we recorded net income of $29.7 million, net income per diluted share of $1.75 and adjusted net income per diluted share of $1.74. The corresponding segment results are on Slide 7. The key takeaway is that on a consolidated basis, the business performed well with lower cost, stronger operating performance driving a healthy improvement in profitability. Adjusted EBITDA margin rose to 13.6% in the quarter as compared to 12% last year.
Slide 8 is a year-over-year comparison of the segment income and adjusted EBITDA for our paperboard business. On a year-over-year basis, higher pricing offset higher cost, while lower production volumes impacted cost absorption and our overall cost structure.
Slide 14 in the appendix shows the sequential comparison of the second quarter to the first quarter of this year. It reflects a lower sales mix, lower production volumes with flattening costs.
Slide 9 is a year-over-year comparison of segment income and adjusted EBITDA for our tissue business. As Arsen discussed, we are benefiting from previously announced price increases, higher volume and lower input costs. It is important to note that significant pulp price increases in 2022 did not impact our financials until the second half of the year, leading to a relatively flat cost comparison between the second quarter of this year to last year.
Slide 15 in the appendix shows the sequential comparison of the second quarter to the first quarter of this year. It reflects the significant benefits that we are seeing from lower input costs particularly in pulp, energy and transportation.
Slide 10 outlines our capital structure. Our balance sheet remains very strong, and our liquidity improved quarter-over-quarter, now totaling $313 million. During the quarter, we generated $33 million in free cash flow and reduced net debt by $25 million versus the first quarter. On a year-to-date basis, we generated $3 million in free cash flow. As a reminder, we had negative cash flows during the first quarter due to a higher-than-normal trade payables balance from the fourth quarter of 2022 as well as typical first quarter outflows.
Our net debt-to-EBITDA ratio was at 2.1x at the end of the quarter. We used free cash flow to repurchase 8 million of our stock during the quarter. That translates into over 260,000 shares repurchased an average price of $31.70 per share. We have roughly $15 million left on our share repurchase authorization.
Let's now move to Slide 11. And for an outlook on the third quarter of 2023 as well as some updates to our full year expectations. Based on the continued momentum in tissue and moderating input costs, we expect adjusted EBITDA in the range of $73 million to $83 million for the quarter. In terms of our full year assumptions, we expect that operating results will be favorable relative to 2022 by $42 million due to fewer major maintenance outages and better operating performance.
Additionally, we now expect a benefit of $15 million to $25 million due to the impact of previously announced price increases and lower input costs. Lastly, our other key assumptions for the full year remain unchanged. Interest expense should be in the $27 million to $25 million range, depreciation and amortization expense should be $98 million to $101 million, capital expenditures should be between $70 million and $80 million, which includes approximately $9 million on our Lewiston recovery boiler tube replacement project and $11 million on the precipitator replacement in Arkansas. As a reminder, the recovery boiler project will require approximately $40 million in total spend, while the precipitator is projected to require $45 million. And finally, our tax rate should be in the mid-20% range.
Let me turn the call back over to Arsen.
Arsen S. Kitch
Thanks, Becky. I'd like to conclude the call with a brief overview of how we're prioritizing our capital allocation to create shareholder value.
Slide 12 is a framework to our approach. Our top priority is sustaining the competitiveness of our assets. We believe that this requires an average of $60 million to $70 million annually, excluding large projects such as the recovery boiler work in Lewiston and the precipitator replacement in Arkansas. Second, we intend to maintain a balance sheet that provides us with financial flexibility. We now have a much stronger balance sheet than we did a few years ago, and we intend to continue to maintain and improve our position. A strong balance sheet provides us with the capacity to take advantage of investment opportunities, including in the potential down cycle. And finally, we will look at various opportunities to create value through return-generating investments, opportunistic acquisitions and returning capital to shareholders.
You saw us do that in the second quarter by repurchasing $8 million worth of our shares. We're going to continue to be disciplined allocators of capital, and we'll seek the right opportunities to create value across both of our businesses. The team delivered a strong second quarter, and we're optimistic about our business in the second half of this year. Let me close by thanking our people for all that they do to keep our operations running safely and efficiently. I would also like to thank our customers for placing their trust in us and our shareholders for their continued support.
With that, we will end our prepared remarks and take your questions.
Question and Answer Session
Operator
(Operator Instructions)
Your first question comes from Paul Quinn from RBC Capital Markets.
Paul C. Quinn
Just maybe start with your Consumer Products segment. The staff for the second quarter came out this morning, it sort of shows pretty lackluster North American tissue production and drop in operating rates. How are you able to -- it sounds like your tissue is going (inaudible), especially in the second quarter. How are you able to compete the competition right now?
Arsen S. Kitch
I think our demand is pretty strong and pretty stable. And as I've mentioned previously, we have no material contract risks this year. So private branded shares up, our customers, generally speaking, are doing well, and I think we're doing a really good job of supporting them. So we have strong sales, and I think the operating rates in the industry are also fairly -- are fairly high. So it's -- for us, at least, our demand is strong, and we're able to support that demand.
Paul C. Quinn
Okay. And then slide, I think it's 15 shows sort of a sequential improvement in that $15 million drop in cost. Is that all to do with pulp?
Arsen S. Kitch
A lot of it is pulp. We're also benefiting from transportation and energy as well in tissues sequentially, but pulp is going to be a big story this year.
Paul C. Quinn
Okay. And then Arsen, you mentioned that 3-month lag in pulp to really hit the bottom line. So this is really the drop in pulp pricing in Q1 that really comes into factor that $15 million in Q2?
Arsen S. Kitch
That's part of the story. So it's -- if we go back on pulp, there's 2 important points there, Paul. The first one is pulp peaked in the second half of last year. And as you mentioned, it takes us approximately 3 months for that to flow through our P&L. So actually, if you look at the first half of this year versus the first half of last year, our pulp prices are actually slightly higher, but we're seeing a meaningful sequential drop in pulp prices.
Paul C. Quinn
Okay. And then if I just switch over to the paperboard side. You mentioned the drop in folding carton pricing, index pricing. When you mentioned that your 35% to 40% index RISI, is that to that folding carton price? Or is that to another RISI index price?
Arsen S. Kitch
I think, generally speaking, it's folding carton and cup. I think those are the 2 prices that RESI indexes. So we're depending on the customer and depending on the volume, it's one of those.
Paul C. Quinn
Okay. And then just on the CapEx spread that you've got, I suspect the precipitator down in Arkansas is kind of a maintenance type thing, you're not expected to get any kind of lower costs or benefits as a result of that. What about the recovery boiler, any pickup in lower cost going forward?
Arsen S. Kitch
I think, generally speaking, both of these are maintenance types of projects. There's probably some mild benefits with the precipitator, but we view that as largely a replacement project. We're replacing something that's decades old. So there should be some better performance coming out of it and better reliability. But largely, we view those as the replacement projects.
Paul C. Quinn
Okay. And then the last question I had, just on capital allocation. I mean, it looked like your balance sheet is in great shape. Why not repurchase a heck a lot more shares than [263] in the quarter?
Arsen S. Kitch
Paul, as I mentioned in our framework, I think we take an opportunistic approach to our share buybacks. So we'll -- we increase our purchases when we see a better value. So we purchased quite a bit -- quite a few more shares this quarter than last quarter, but I'll just leave it at that.
Paul C. Quinn
Well, it seems to reckon that given the share price is right about what you purchased the shares in Q2. I suspect you've got a clear opportunity into Q3 as well.
Arsen S. Kitch
Well, we'll continue to look at that and buy back shares up our opportunistic call.
Operator
Ladies and gentlemen, that concludes today's call. Thank you all for joining, and you may now disconnect.
